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Abstract
Background: Tripe palms is a descriptive term for a
cutaneous paraneoplastic keratoderma. Tripe palms are
frequently associated with gastric and pulmonary carci-
noma. The pathogenetic mechanism remains unknown.
Objective: To determine the influence of receptor tyro-
sine kinases, which are both expressed in pulmonary
carcinomas and in human skin, we performed expres-
sion studies on epidermal growth factor receptor (EGFR),
HER2, HER3 in a skin sample of tripe palms obtained
from a patient with non-small-cell lung cancer with
lymph node involvement. Two months after diagnosis,
the patient had developed palmoplantar ‘tripe palms’.
Additionally, the expression of SRC, c-myc and p16/
CDKN2 were studied. Method: Conventional reverse-
transcription polymerase chain reaction was performed
on a tissue sample of tripe palms. Results: Weak expres-
sion of HER2 and of p16/CDKN2 was found. EGFR, HER3,
c-myc and SRC were not expressed. Conclusion: Recep-
tor tyrosine kinases of subclass I, the tyrosine kinase SRC
and the oncogene c-myc play no major role in the patho-
genesis of this case of tripe palms.
Copyright ® 2000 S. Karger AG, Basel
Tripe palms is a descriptive term for a rare cutaneous
paraneoplastic keratoderma referring to the rugose surface
of bovine foregut, which when prepared as food is known
as tripe. The term was first introduced in 1977 by J. Clark
[1]. The disease is characterized by thickening of the epi-
dermis leading to a velvety texture and the accentuation of
the normal dermatoglyphic ridges and sulci of palms and
soles. Tripe palms are most frequently associated with gas-
tric cancer (27%) and, as in our case, pulmonary carcinoma
(22%) [2, 3]. Approximately 80 cases of tripe palms [1–8]
have been described in the literature, not only in association
with gastric and pulmonary carcinoma but also with e.g.
melanomas, lymphomas, carcinomas of the entire gastro-
intestinal tract and urogenital tract, mammary carcinomas
and carcinomas of the central nervous system. The isolated
occurrence of tripe palms is more frequently found in pul-
monary carcinoma, whereas 55% of patients with the com-
bination of tripe palms and acanthosis nigricans suffer from
gastric carcinoma [9]. In contrast to our patient, tripe palms
in most cases develop prior to the diagnosis of the malignant
disease [10]. Tripe palms are known to be a paraneoplastic
disease, the pathogenesis, however, remains obscure. It has
been speculated that the human growth hormone or related
proteins, epidermal growth factor (EGF) or tissue growth
factor a (TGF-a ) may cause tripe palms [1, 11–13]. In order
to elucidate the pathogenetic role of receptor tyrosine
kinases (RTKs), which represent binding sites for EGF and
TGF-a , we studied the expression of EGF receptor (EGFR),
HER2, HER3 as well as SRC, a tyrosine kinase activated by
RTKs in the signal transduction process. The oncogene
Clinical and Laboratory Investigations
Dermatology 1999;199:290–295 Received: March 22, 1999
Accepted: August 12, 1999
c-myc involved in the regulation of apoptosis as well as the




A 67-year-old Caucasian presented with chronic obstructive pul-
monary disease, due to nicotine abuse and a mediastinal tumour, diag-
nosed as a non-small-cell lung cancer (NSCLC) with infiltration of the
ganglion cervicale superius as well as cervical and mediastinal lymph
nodes. Two months after diagnosis the patient developed hyperkeratotic,
light yellow, velvety, non-pruritic skin changes starting on the palms fol-
lowed by similar less severe skin alterations on the soles. No surgical
therapy on the primary tumour or the lymph nodes was performed. Both
chemotherapy (carboplatin and paclitaxel) and radiation therapy were
performed, leading to a reduction of tumour size of 25% and a 50%
reduction of lymph node involvement. Despite this partial remission the
hyperkeratotic skin alterations remained unchanged, arguing for a con-
tinuing stimulus which – in this case – was independent of tumour size.
Routine laboratory findings and human growth hormone were within the
normal range. There were no endocrinological disorders such as
acromegaly, Cushing’s syndrome or diabetes mellitus.
On the palms and, to a lesser degree, the soles, a yellowish, velvety
hyperkeratosis with accentuation of the dermatoglyphic lines with iso-
lated hyperkeratotic papules and ‘pits’ was seen. Clubbing of the distal
fingers, symmetric onychodystrophy and palmar hyperhydrosis were
diagnosed (fig. 1, 2). There were no signs of acanthosis nigricans on
the trunk.
Dermatopathology revealed regular acanthosis and psoriasiform
papillomatosis with orthohyperkeratosis. PAS staining was negative.
Considering the poor prognosis of lung cancer (fig. 3), we did not
administer etretinate [14, 15]. There was considerable improvement
using a topical application of salicylic acid and urea-containing oint-
ments.
Reverse-Transcription Polymerase Chain Reaction Analysis of
EGFR, HER2, HER3, C-myc, SRC and p16/CDKN2
To elucidate the role of RTKs as well as SRC, c-myc and
p16/CDKN2 in this case of tripe palms, we performed conventional
reverse-transcription polymerase chain reaction (RTPCR) on a punch
biopsy from the left palm (fig. 4).
Material
An N2-frozen tissue specimen taken from the left palm of this male
Caucasian suffering from tripe palms was studied. Since no surgery
was performed on the NSCLC, an expression study on the underlying
tumour tissue was impossible.
Methods
The tissue sample was shock frozen in liquid nitrogen immediately
after excision. The tissue was minced, total mRNAs were isolated from
homogenates using the RNA-Clean™ System (Angewandte Gentech-
nologie Systeme GmbH, Germany). Using oligo (dt) primers, the
extracted mRNA was transcribed with the Reverse Transcriptase Sys-
tem (Promega) to cDNA. The cDNAs were then phenol/chloroform
extracted, precipitated by ethanol extraction and redissolved in ddH2O.
The cDNA concentration was measured by absorbance at 260 nm. In
subsequent PCR reactions (25 µl), 100 ng cDNA template from above
was used to investigate the expression of the following genes. The
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Fig. 1. Tripe palms, palmar aspect.
Fig. 2. Accentuation of the normal dermato-
glyphic ridges and sulci.
1 2
sense and antisense strand primers and cycling parameters used to
detect transcripts were as follows:
EGFR: 5¢ -ACT AGC CAG GAA CTA CTT CC-3¢ and 5¢ -GGC
CTT CTT GGA TCT TTA GT-3¢ , predicted product size: 398 bp,
cycling parameters: a first heating step (94 °C, 4 min), followed by
93 °C for 35 s, 60 °C for 35 s, 72 °C for 35 s, 35 cycles and one final
extension step (68 °C, 10 min); HER2: 5¢ -CGG GAG ATC CCT GAC
CTG CTG GAA-3¢ and 5¢ -CTG CTG GGG TAC CAG ATA CTC
CTC-3¢ , predicted product size: 300 bp, cycling parameters: a first
heating step (94 °C, 4 min), followed by 93 °C for 35 s, 60 °C for 35 s,
72 °C for 35 s, 35 cycles and one final extension step (68 °C, 10 min);
HER3: 5¢ -CUA CUA CUA CUA GAG GCT GAG CTC CAG GAG
AA-3¢ and 5¢ - CAU CAU CAU CAU CTG GGA CCT GGG AGA
GAG AG-3¢ , predicted prodcut size: 814 bp, cycling parameters: a first
heating step (94 °C, 4 min), followed by 93 °C for 35 s, 56 °C for 35 s,
72 °C for 35 s, 35 cycles and one final extension step (68 °C, 10 min);
SRC: 5¢ -CAG ACC TGT CCT TCA AGA AA-3¢ and 5¢ -TCA GCC
TGG ATG GAG TCG GA-3¢ , predicted product size: 162 bp, cycling
parameters: a first heating step (94 °C, 4 min), followed by 93 °C for
35 s, 59 °C for 35 s, 72 °C for 35 s, 35 cycles and one final extension
step (68 °C, 10 min); c-myc: 5 ¢ -CCA GCA GCG ACT CTG AGG-3 ¢
and 5 ¢ -CCA AGA CGT TGT GTG TTC-3¢ , predicted product size:
345 bp, cycling parameters: a first heating step (94 °C, 4 min), fol-
lowed by 93 °C for 35 s, 60 °C for 35 s, 72 °C for 35 s, 35 cycles and one
final extension step (68 °C, 10 min); p16/CDKN2: 5¢ -ATC CTG ACT
GCT GTC ATG GC-3¢ and 5 ¢ -ACT CTT GGA AGT CCA CCT CG-3 ¢ ,
predicted product size: for cDNA 238 bp and genomic CNA 959 bp,
cycling parameters: a first heating step (94 °C, 4 min), followed by
93 °C for 35 s, 60 °C for 35 s, 72 °C for 35 s, 35 cycles and one final
extension step (68 °C, 10 min).
The PCR products had been sequenced.
The PCR mixtures contained 100 ng of template cDNA, 1.5 mM
MgCl2, 1 µm/25 µl sense and antisense primer, 0.2 mM dNTPs (Pro-
mega) and Taq polymerase 1 unit (Boehringer, Mannheim, Germany).
To circumvent false-negative results, we used primers detecting the
GAPDH gene (Stratagene); sense 5¢ -CCA CCC ATG GCA AAT TCC
ATG GCA-3¢ ; antisense 5¢ -TCT AGA CGG CAG GTC AGG TCC
ACC-3¢ , predicted product size: 598 bp, cycling parameters: a first
heating step (94 °C, 4 min), followed by 93 °C for 35 s, 60 °C for 35 s,
72 °C for 35 s, 35 cycles and one final extension step (68 °C, 10 min).
The DNA molecular-weight standard (PhiX 174RF/HaeIII) was pur-
chased from Boehringer Mannheim. RNA from the melanoma cell line
C32, obtained from the American Type Culture Collection, was ampli-
fied as a positive control. The cell line was cultured as recommended
by the American Type Culture Collection. Water instead of cDNA was
applied as a negative control. In parallel genomic DNA was amplified.
Following PCR, identical aliquots (5 µl) were loaded on 2% agarose
gels and the products were visualized by ethidium bromide staining.
The optical density of bands was analysed by a computerized densito-
metric analysis device (Image master VDS, Pharmacia). The expres-
sion level of the genomic DNA was taken as a level for determining
‘weakly positive’ or ‘positive’ expression. Optical density in the ethid-
ium bromide gel lower than the genomic DNA band was regarded as
‘weak’, similar or higher as ‘positive’. Genomic contamination was
ruled out by the use of p16/CDKN2 primers with different product
sizes for cDNA (238 bp) and genomic DNA (959 bp).
Results
The housekeeping gene GAPDH was strongly expressed.
Weak expression of HER2 was detectable in the tripe palms
sample, while EGFR and HER3 expression was not found.
In 105 previously tested samples of normal skin, naevi and
malignant melanoma, HER2 expression was detectable in
all samples regardless of the dignity of the tissue (data not
shown).
SRC, a tyrosine kinase involved in signal transduction
downstream of RTKs [16], was not detectable either.
c-myc, an oncogene involved in a variety of malignant
tumours [17], was not expressed. p16/CDKN2 [18, 19], a
tumour suppressor gene [20], was moderately expressed.
Since different product sizes for cDNA and genomic DNA
are produced with these applied primers, genomic contami-
nation could be ruled out.
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Fig. 3. Chest X-ray, NSCLC (mediastinal).
Fig. 4. PCR products. TP = Tripe palms.
Discussion
It has been speculated that the human growth hormone or
related proteins may cause tripe palms [1]. In 2 cases, high
levels of immunoreactive human growth hormone were
detected. The elevated level of this hormone may act as a
mediator for the hypertrophic processes. Elevated levels of
immunoreactive human growth hormone have also been
described in patients with lung cancer. Since elevated
human growth hormone as well as plasma growth-hormone-
releasing hormone have been detected in serum of patients
both with small-cell and non-small-cell lung carcinoma [21]
without tripe palms, the development of tripe palms is not
necessarily caused by the human growth hormone.
Based on the observation of an elevated EGF level in a
patient with tripe palms in association with bronchial carci-
noma, the role of tumour growth factors such as EGF has
been discussed [11]. The overexpression of EGF in the
serum of this published patient [11] could be attributable to
the underlying malignant process, since elevated EGF levels
were also detected in patients with lung carcinoma [22]
without tripe palms.
Publications attributing a pathogenetic influence of the
TGF-a to the development of acanthosis nigricans, a para-
neoplastic skin disease with similarity to tripe palms, are
based on the detection of TGF-a in tumour tissue but not in
the skin samples [12, 13]. A case report on a patient with
systemic mastocytosis and tripe palms describes elevated
serum levels of TGF-a and mast cells in the skin [8].
A recent concept [16] assumes that the activation of
membrane-based receptor tyrosine kinases by binding of
ligand such as EGF or TGF-a leads to the induction of sig-
nal transduction processes resulting in cell proliferation and
differentiation. An elevated level of EGF or TGF-a should
thus result in the expression of corresponding receptors such
as the EGFR, expressed in a variety of malignant tumours
including pulmonary carcinoma [23] and melanoma [24],
or HER2, an important oncogene in mammary carcinoma
[25, 26], or HER3 [27, 28], a closely related member of this
gene family [29], expressed among others in head and neck
tumours. These RTKs of subclass I are also designated
erbB1–3. A further member, HER4 [30], has not yet been
extensively studied in human carcinomas in vivo.
Based on these data, we investigated the role of RTKs of
subclass I, which could be putative receptors for ligands
such as EGF in this case of tripe palms.
Recent studies provide evidence that the family I of
RTKs can associate with each other to form an array of het-
erodimer complexes [31–36]. Therefore, the activation of
one receptor could modulate the activity of the other mem-
bers of this group of RTKs when co-expressed in a cell and
extend the repertoire of downstream signalling events.
HER2 can – in the absence of any HER2-specific ligand –
be transmodulated within a heterodimer complex by asso-
ciating with other HER family members. Tzahar et al. [31]
came to the conclusion that HER2 might serve as the
preferred heterodimerizing partner of the three other ERBb
proteins.
In this case of tripe palms EGFR and HER3 are not
involved in this signal transduction process. HER2 is
expressed in this case of tripe palms. Isolated expression of
HER2 could theoretically – by homodimerization – be suffi-
cient to activate signal transduction downstream of the
RTKs. HER4 [30], a further RTK of subclass I which we did
not test, as well as other yet unidentified RTKs might be
possible candidates for further partners for heterodimer-
ization with HER2. However, HER4 has not yet been
described in adult skin or any skin cancer [37]. The lack of
SRC expression hints at another signal transduction path-
way activated by RTKs than the one via SRC.
HER2 expression both in vitro and in vivo has been
described in NSCLC [38–42]. We found weak to strong
HER2 expression in more than 100 skin samples of varying
dignity (data not shown), and frequent HER2 protein
expression has been described both in benign and malignant
cutaneous tissue [43–45]. Despite the known HER2 expres-
sion in NSCLC, but due to the frequent HER2 expression in
cutaneous tissue and its weak expression in this particular
case, HER2 might not be a causative factor for NSCLC-
associated paraneoplastic skin diseases, such as tripe palms.
c-myc, a transcription factor that is believed to regulate
the expression of genes governing cellular growth, differen-
tiation and apoptosis [17, 46, 47] is – due to a lack of its
expression – presumably not involved in regulatory mecha-
nisms in this case of tripe palms.
Interestingly, p16/CDKN2, a cell cycle regulator with
tumour suppressor activity [18–20], among others in malig-
nant melanoma, was expressed in this case of tripe palms.
The role of further cell cycle regulators with tumour sup-
pressor gene potential such as p53 need to be elucidated in
further studies.
Our data demonstrate that EGFR, HER3, c-myc and SRC
are not involved in the pathogenesis of this case of tripe
palms. Whether HER2 homodimer formation or the possi-
ble involvement of further RTKs [32] is responsible for tripe
palms will have to be studied. Except for ligands such as
EGF or TGF-a , which have been detected in patients with
tripe palms, yet uninvestigated RTK ligands such as hereg-
ulin [48] might furthermore play a role in the pathogenesis
of tripe palms.
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Although the pathogenetic mechanisms causing tripe
palms remain unclear, further studies on gene expression of
growth factors and their ligands, with special respect to
those involved in the underlying malignant neoplasias, may
help to understand the intriguing pathways leading to para-
neoplastic skin diseases.
From a clinical point of view the knowledge of tripe
palms is crucial, since in 40% of patients, tripe palms are the
presenting feature of a previously undiagnosed malignant
neoplasia [10]. The observation of tripe palms should thus
always prompt a meticulous search for an underlying malig-
nancy.
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